Vanderbilt University scientists have contributed to a major finding, reported in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.The Vanderbilt scientists and others analyzed in an animal model a new method developed at The Scripps Research Institute (TSRI) in La Jolla, Calif., for designing artificial proteins capable of stimulating an immune response against RSV.

More...